Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hypoglycemia Overview 8 Therapeutics Development 9 Pipeline Products for Hypoglycemia - Overview 9 Hypoglycemia - Therapeutics under Development by Companies 10 Hypoglycemia - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Hypoglycemia - Products under Development by Companies 15 Hypoglycemia - Companies Involved in Therapeutics Development 16 Biodel Inc. 16 Eiger BioPharmaceuticals, Inc. 17 Eli Lilly and Company 18 Heptares Therapeutics Limited 19 Novartis AG 20 Sanofi 21 SkyePharma Plc 22 Therakind Limited 23 USV Limited 24 XERIS Pharmaceuticals, Inc. 25 XOMA Corporation 26 Zealand Pharma A/S 27 Zosano Pharma Corporation 28 Hypoglycemia - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 Drug for Hypoglycemia - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 exendin-(9-39) - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 glucagon - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 glucagon - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 glucagon - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 glucagon - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 LY-3143753 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 LY-3185643 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 LY-900018 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 pasireotide - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Recombinant Peptide for Hypoglycemia - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 SAR-438544 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 terbutaline sulphate MR - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 XOMA-129 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 XOMA-358 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 ZP-4207 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Hypoglycemia - Dormant Projects 64 Hypoglycemia - Discontinued Products 65 Hypoglycemia - Product Development Milestones 66 Featured News & Press Releases 66 Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia 66 May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery 66 Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery 67 Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting 67 Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes 68 Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism 68 Oct 13, 2015: Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia 69 Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand’s stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia 69 Jun 26, 2015: Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy 70 Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia 71 May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207 71 Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial 72 Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting 73 Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 74 Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program 75 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 76 Disclaimer 77

List of Tables Number of Products under Development for Hypoglycemia, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Hypoglycemia - Pipeline by Biodel Inc., H2 2016 16 Hypoglycemia - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2016 17 Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2016 18 Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H2 2016 19 Hypoglycemia - Pipeline by Novartis AG, H2 2016 20 Hypoglycemia - Pipeline by Sanofi, H2 2016 21 Hypoglycemia - Pipeline by SkyePharma Plc, H2 2016 22 Hypoglycemia - Pipeline by Therakind Limited, H2 2016 23 Hypoglycemia - Pipeline by USV Limited, H2 2016 24 Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016 25 Hypoglycemia - Pipeline by XOMA Corporation, H2 2016 26 Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2016 27 Hypoglycemia - Pipeline by Zosano Pharma Corporation, H2 2016 28 Assessment by Monotherapy Products, H2 2016 29 Number of Products by Stage and Target, H2 2016 31 Number of Products by Stage and Mechanism of Action, H2 2016 33 Number of Products by Stage and Route of Administration, H2 2016 35 Number of Products by Stage and Molecule Type, H2 2016 37 Hypoglycemia - Dormant Projects, H2 2016 64 Hypoglycemia - Discontinued Products, H2 2016 65 List of Figures Number of Products under Development for Hypoglycemia, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Assessment by Monotherapy Products, H2 2016 29 Number of Products by Targets, H2 2016 30 Number of Products by Stage and Targets, H2 2016 30 Number of Products by Mechanism of Actions, H2 2016 32 Number of Products by Stage and Mechanism of Actions, H2 2016 32 Number of Products by Routes of Administration, H2 2016 34 Number of Products by Stage and Routes of Administration, H2 2016 34 Number of Products by Molecule Types, H2 2016 36 Number of Products by Stage and Molecule Types, H2 2016 36

Biodel Inc. Eiger BioPharmaceuticals, Inc. Eli Lilly and Company Heptares Therapeutics Limited Novartis AG Sanofi SkyePharma Plc Therakind Limited USV Limited XERIS Pharmaceuticals, Inc. XOMA Corporation Zealand Pharma A/S Zosano Pharma Corporation